What is DaShenLin Pharmaceutical Group Co Net Margin %?
DaShenLin Pharmaceutical Group CoSHSE:603233 -4.01%95 Net Margin % is 7.33% as of Mar. 2026, which is 35% above its 10-year median of 5.44. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.69 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks better than 59.4% on this metric.
The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's Net Margin % or its related term are showing as below:
SHSE:603233'
s Net Margin % Range Over the Past 10 Years
Min: 3.45 Med: 5.44 Max: 7.28
Current: 4.67
SHSE:603233's Net Margin % is ranked better than 59.4% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 2.89
vs SHSE:603233: 4.67
DaShenLin Pharmaceutical Group Co (SHSE:603233) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
DaShenLin Pharmaceutical Group Co Net Margin % Related Terms
DaShenLin Pharmaceutical Group Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co Net Margin % Chart
DaShenLin Pharmaceutical Group Co Net Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Net Margin % of 7.33% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is 35% above median its historical median of 5.44. Over the past decade, DaShenLin Pharmaceutical Group Co's Net Margin % has ranged from 3.45 to 7.28. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #270 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 40.6%.
Is DaShenLin Pharmaceutical Group Co's Net Margin % too high?
DaShenLin Pharmaceutical Group Co's current Net Margin % of 7.33% is 35% above median its 10-year median of 5.44. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 7.28. The Healthcare Providers & Services industry median Net Margin % is 2.89. DaShenLin Pharmaceutical Group Co's value of 7.33% is 153.6% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #270 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Net Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #270 out of 665 companies for Net Margin %. This puts DaShenLin Pharmaceutical Group Co in the upper half of its industry. The industry median Net Margin % is 2.89. DaShenLin Pharmaceutical Group Co's value of 7.33% is 153.6% above this benchmark. Historically, DaShenLin Pharmaceutical Group Co's own Net Margin % has ranged from 3.45 to 7.28 over the past decade. While the company's 10-year median is 5.44 vs. the industry median of 2.89, DaShenLin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current Net Margin % of 7.33% is 153.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current Net Margin % is 7.33%, which is 35% above median its own 10-year median of 5.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.69, compared to a current price of ¥14.86 — trading 20.5% below its estimated fair value. The current Net Margin % is 7.33%, which is 35% above median its 10-year median of 5.44 and 153.6% above the Healthcare Providers & Services industry median of 2.89. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Net Margin % is 7.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥14.86 is trading 20.5% below its estimated GF Value™ of ¥18.69.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:603233:
Net Margin %: 7.33% (35% above median its 10-year median of 5.44)
GF Value™: ¥18.69 vs. price of ¥14.86 (20.5% below fair value)
Industry Position: 153.6% above the Healthcare Providers & Services median (#270 of 665)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score
Get the complete analysis for SHSE:603233
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
